IN2012MN02923A - - Google Patents

Info

Publication number
IN2012MN02923A
IN2012MN02923A IN2923MUN2012A IN2012MN02923A IN 2012MN02923 A IN2012MN02923 A IN 2012MN02923A IN 2923MUN2012 A IN2923MUN2012 A IN 2923MUN2012A IN 2012MN02923 A IN2012MN02923 A IN 2012MN02923A
Authority
IN
India
Prior art keywords
dosage forms
present
gaba
gastroretentive dosage
swelling
Prior art date
Application number
Other languages
English (en)
Inventor
Pratibha Sudhir Pilgaonkar
Maharukh Tehmasp Rustomjee
Anilkumar Surendrakumar Gandhi
Original Assignee
Rubicon Res Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rubicon Res Private Ltd filed Critical Rubicon Res Private Ltd
Priority to IN2923MUN2012 priority Critical patent/IN2012MN02923A/en
Publication of IN2012MN02923A publication Critical patent/IN2012MN02923A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN2923MUN2012 2010-06-01 2011-06-01 IN2012MN02923A (enrdf_load_html_response)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IN2923MUN2012 IN2012MN02923A (enrdf_load_html_response) 2010-06-01 2011-06-01

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1676MU2010 2010-06-01
PCT/IB2011/001200 WO2011151708A1 (en) 2010-06-01 2011-06-01 Gastroretentive dosage forms of gaba analogs
IN2923MUN2012 IN2012MN02923A (enrdf_load_html_response) 2010-06-01 2011-06-01

Publications (1)

Publication Number Publication Date
IN2012MN02923A true IN2012MN02923A (enrdf_load_html_response) 2015-06-05

Family

ID=54199435

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2923MUN2012 IN2012MN02923A (enrdf_load_html_response) 2010-06-01 2011-06-01

Country Status (4)

Country Link
US (1) US20130078290A1 (enrdf_load_html_response)
EP (1) EP2575798B1 (enrdf_load_html_response)
IN (1) IN2012MN02923A (enrdf_load_html_response)
WO (1) WO2011151708A1 (enrdf_load_html_response)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013213859A1 (en) 2012-01-30 2014-08-21 Sun Pharmaceutical Industries Limited Pregabalin GR tablets
WO2013114283A1 (en) 2012-01-30 2013-08-08 Ranbaxy Laboratories Limited Gastroretentive tablets
EP2698144A1 (en) * 2012-08-12 2014-02-19 Ali Raif Ilaç Sanayi ve Ticaret Anonim Sirketi Prolonged release gabapentin tablet formulation whose ability to stay in the stomach is improved
EP2908803A1 (en) 2012-10-16 2015-08-26 Ranbaxy Laboratories Limited Osmotic floating tablets
FR3014692B1 (fr) * 2013-12-18 2016-01-29 Ethypharm Sa Compositions pharmaceutiques orales a retention gastrique.
WO2015114509A1 (en) * 2014-01-28 2015-08-06 Ranbaxy Laboratories Limited Stabilized gastroretentive tablets of pregabalin
KR102221846B1 (ko) * 2014-04-07 2021-02-26 영진약품 주식회사 안정성이 개선된 프레가발린을 함유하는 약제학적 조성물 및 이의 제조방법
WO2015174684A1 (ko) * 2014-05-14 2015-11-19 동아에스티 주식회사 방출제어된 위체류 서방성 제제
EP3355865B8 (en) 2015-09-29 2025-02-19 Merz Pharmaceuticals, LLC Sustained release compositions of 4-aminopyridine
CA3016851A1 (en) * 2016-03-10 2017-09-14 Orphelia Pharma Solid dosage forms of vigabatrin
WO2018001582A1 (en) * 2016-06-30 2018-01-04 Interquim, S.A. Ranolazine multiple compressed tablets
KR102039344B1 (ko) * 2017-02-01 2019-11-01 지엘팜텍주식회사 프레가발린 함유 경구용 서방성 삼중정제
KR102039345B1 (ko) 2017-02-01 2019-11-01 지엘팜텍주식회사 프레가발린 함유 고팽윤성 서방성 삼중정제
KR102083241B1 (ko) * 2018-02-14 2020-03-02 환인제약 주식회사 라코사미드를 함유하는 약제학적 서방성 조성물
WO2019238068A1 (zh) * 2018-06-13 2019-12-19 北京泰德制药股份有限公司 一种普瑞巴林缓释组合物及其制备方法
US11147767B2 (en) * 2019-02-25 2021-10-19 Rubicon Research Private Limited Gastroretentive formulations
PT3760190T (pt) 2019-07-03 2023-07-31 Alvogen Inc Comprimidos de libertação controlada de pregabalina, método de preparação e método de utilização dos mesmos
CN112741827B (zh) * 2019-10-31 2022-07-08 武汉武药科技有限公司 氨己烯酸固体制剂及其制备方法
IL310523A (en) * 2021-07-30 2024-03-01 Evecxia Therapeutics Inc 5-hydroxytryptophan gastroretentive dosage forms
US12409163B2 (en) 2021-07-30 2025-09-09 Evecxia Therapeutics, Inc. Method of enhancing 5-hydroxytryptophan (5-HTP) exposure
US11779567B2 (en) 2021-10-14 2023-10-10 Evecxia Therapeutics, Inc. Method for optimizing 5-hydroxytryptamine function in the brain for therapeutic purposes
CN114796142A (zh) * 2022-04-08 2022-07-29 黄山学院 萘普生胃漂浮片及其制备方法
WO2024148354A1 (en) * 2023-01-06 2024-07-11 Evecxia Therapeutics, Inc. A method of enhancing 5-hydroxytryptophan (5-htp) exposure

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4087544A (en) 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
DE2460891C2 (de) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US5084479A (en) 1990-01-02 1992-01-28 Warner-Lambert Company Novel methods for treating neurodegenerative diseases
US5025035A (en) 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
US6197819B1 (en) 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
US5232704A (en) * 1990-12-19 1993-08-03 G. D. Searle & Co. Sustained release, bilayer buoyant dosage form
US5510381A (en) 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder
NZ332762A (en) 1996-07-24 2000-09-29 Warner Lambert Co Isobutylgaba and its derivatives for the treatment of pain
HRP980342A2 (en) 1997-06-25 1999-02-28 Warner Lambert Co Anti-inflammatory method
JP2001527023A (ja) * 1997-08-11 2001-12-25 アルザ・コーポレーション 胃で保持するのに適合した長期放出性活性剤剤形
US6127418A (en) 1997-08-20 2000-10-03 Warner-Lambert Company GABA analogs to prevent and treat gastrointestinal damage
AU2002355686B2 (en) 2001-07-04 2007-11-29 Sun Pharmaceutical Industries Limited Gastric retention controlled drug delivery system
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
CN1668284A (zh) * 2002-06-07 2005-09-14 兰贝克赛实验室有限公司 加巴喷丁的缓释口服剂型
NL2000281C2 (nl) * 2005-11-02 2007-08-07 Pfizer Prod Inc Vaste farmaceutische samenstellingen die pregabaline bevatten.
JP2009522294A (ja) * 2005-12-29 2009-06-11 デポメッド， インコーポレイテッド 胃保持型ガバペンチン投薬形態およびその使用方法
WO2009084040A1 (en) * 2007-12-28 2009-07-09 Rubicon Research Private Limited Once a day formulation of angiotensin receptor blockers
US9693981B2 (en) * 2008-12-04 2017-07-04 Intec Pharma Ltd. Zaleplon gastroretentive drug delivery system
RU2012100709A (ru) 2009-06-12 2013-07-20 Майкро Лэбз Лимитед Новые фармацевтические композиции, содержащие прегабалин
KR101317592B1 (ko) 2009-10-28 2013-10-15 씨제이제일제당 (주) 프레가발린, 폴리에틸렌옥사이드 및 폴리비닐알코올-폴리에틸렌글리콜 그라프트 공중합체를 함유하는 위체류형 서방성 제제

Also Published As

Publication number Publication date
EP2575798B1 (en) 2017-08-09
EP2575798A1 (en) 2013-04-10
WO2011151708A1 (en) 2011-12-08
US20130078290A1 (en) 2013-03-28

Similar Documents

Publication Publication Date Title
IN2012MN02923A (enrdf_load_html_response)
MY183588A (en) New salvianolic acid compound l, preparation method and use thereof
PH12015501964A1 (en) Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
PH12015501385A1 (en) Autotaxin inhibitors
MX2010002210A (es) Derivados de catecolamina y profarmacos de los mismos.
MX2012012225A (es) Profármacos de agentes tearapéuticos de liberación de óxido nítrico.
MX2015003653A (es) Derivados de amida del acido benzoimidazol-carboxilico como moduladores del receptor apj.
MX2013001677A (es) Formulaciones estables de linaclotida.
UA109661C2 (uk) Фармацевтична композиція співкристалів трамадолу і коксибів
TN2011000370A1 (en) Alkylamine-substituted dicyanopyridine and amino acid ester prodrugs thereof
MY156288A (en) Pharmaceutical formulations containing dopamine receptor ligands.
MX2019012939A (es) Formulaciones que contienen linaclotida para administracion oral.
PH12012502082A1 (en) Combination of active loaded granules with additional actives
MY157673A (en) Pharmaceutical compositions comprising hydromorphone and naloxone
PH12012502083A1 (en) Manufacturing of active-free granules and tablets comprising the same
PH12015500823A1 (en) Modified release formulations for oprozomib
MX2012008413A (es) Composicion novedosa de retigabina.
UY33723A (es) ?COMPUESTOS Y SU USO PARA TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON Aß?.
PH12013500371A1 (en) Therapeutic agent for pain
TR200909785A1 (tr) Aktif ajan olarak sefdinir içeren farmasötik kompozisyonlar.
PH12013500027A1 (en) Therapeutic agents 976
UY32894A (es) Derivados de 5-fenil-pirazolopiridina, su preparación y su aplicación en terapéutica
EP2563785A4 (en) Compounds as Agonists Against S1P1 Receptors
PH12015502560B1 (en) Use of a thiazolo pyrimidinone for the treatment of inflammatory bowel disease
UA93515C2 (ru) Медикаментозное средство ha ochobe рутина